Munich - Delayed Quote EUR

Esperion Therapeutics Inc (0ET.MU)

Compare
2.1410 0.0000 (0.00%)
At close: January 9 at 8:03:22 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 0ET.MU

Recent News: 0ET.MU

View More
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
GlobeNewswire 16 hours ago
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 7 days ago
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
GlobeNewswire 22 days ago
Esperion Announces $210 Million Convertible Debt Financing

Esperion Announces $210 Million Convertible Debt Financing
GlobeNewswire 27 days ago
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
GlobeNewswire 28 days ago
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Zacks last month
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
GlobeNewswire last month
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
GlobeNewswire last month
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire last month
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
GlobeNewswire last month
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2 months ago
View More

Related Tickers

29A.SG Amphastar Pharmaceuticals Inc
34.71
+4.30%
 
NIKA NIKA PHARMACEUTICALS INC.
0.5900
+16.32%
 
27N0.DU Cannovum Cannabis AG
0.4980
+4.18%
 
11L.MU Canopy Growth Corp. R
2.5800
-7.36%
 
CRFTF BC Craft Supply Co. Ltd.
0.0001
0.00%
 
KN0.F Dicot Pharma AB
0.0235
-4.86%
 
9989.HK Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
3.670
-2.13%
 
R9U2.F Green Thumb Industries Inc.
7.22
-5.25%
 
6CQ.MU Cresco Labs Inc
0.9585
-0.52%
 
RIG2.BE Chemical Works of Gedeon Richter PLC
25.30
-0.63%